These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19934276)

  • 21. Development of the proteasome inhibitor Velcade (Bortezomib).
    Adams J; Kauffman M
    Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
    Momose I; Tatsuda D; Ohba S; Masuda T; Ikeda D; Nomoto A
    Cancer Sci; 2012 Sep; 103(9):1730-6. PubMed ID: 22676179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
    Sunwoo JB; Chen Z; Dong G; Yeh N; Crowl Bancroft C; Sausville E; Adams J; Elliott P; Van Waes C
    Clin Cancer Res; 2001 May; 7(5):1419-28. PubMed ID: 11350913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib.
    Carew JS; Nawrocki ST; Reddy VK; Bush D; Rehg JE; Goodwin A; Houghton JA; Casero RA; Marton LJ; Cleveland JL
    Cancer Res; 2008 Jun; 68(12):4783-90. PubMed ID: 18559525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
    Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib.
    Williamson MJ; Blank JL; Bruzzese FJ; Cao Y; Daniels JS; Dick LR; Labutti J; Mazzola AM; Patil AD; Reimer CL; Solomon MS; Stirling M; Tian Y; Tsu CA; Weatherhead GS; Zhang JX; Rolfe M
    Mol Cancer Ther; 2006 Dec; 5(12):3052-61. PubMed ID: 17172407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential for proteasome inhibition in the treatment of cancer.
    Adams J
    Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Productively combining proteasome inhibition with the immunotherapy of cancer.
    Sayers T
    J Mol Med (Berl); 2008 Aug; 86(8):857-60. PubMed ID: 18612622
    [No Abstract]   [Full Text] [Related]  

  • 31. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
    Houghton PJ; Morton CL; Kolb EA; Lock R; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Jan; 50(1):37-45. PubMed ID: 17420992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model.
    Zhang Y; Saylor M; Wen S; Silva MD; Rolfe M; Bolen J; Muir C; Reimer C; Chandra S
    Mol Imaging Biol; 2006; 8(5):300-8. PubMed ID: 16897318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
    Psallidas I; Karabela SP; Moschos C; Sherrill TP; Kollintza A; Magkouta S; Theodoropoulou P; Roussos C; Blackwell TS; Kalomenidis I; Stathopoulos GT
    Mol Cancer; 2010 Mar; 9():56. PubMed ID: 20219102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
    Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.
    Russo A; Fratto ME; Bazan V; Schiró V; Agnese V; Cicero G; Vincenzi B; Tonini G; Santini D
    Expert Opin Ther Targets; 2007 Dec; 11(12):1571-86. PubMed ID: 18020979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
    Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.
    Huang Z; Wu Y; Zhou X; Xu J; Zhu W; Shu Y; Liu P
    Future Oncol; 2014 Aug; 10(10):1795-807. PubMed ID: 25303058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
    Zou P; Kawada J; Pesnicak L; Cohen JI
    J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.